Medable Wins 2023 Prix Galien Award For Best Digital Health Solution

By Author: Arina Smith
Total Articles: 185
Comment this article

Medable Inc., a prominent technology provider for modern clinical trials, has been recognized with the "Best Digital Health Solution" award at the Prix Galien USA Forum in New York City. The Prix Galien Award is highly esteemed in the life science industry and is often likened to the Nobel Prize. This recognition underscores Medable's commitment to revolutionizing drug development by combining technology and science to expedite the creation of new medications.

Key highlights about Medable and its impact:

1. **Industry-Leading Position**: Medable's evidence generation platform has gained trust and acclaim from the pharmaceutical and clinical research industry. Nine of the top 10 largest Contract Research Organizations (CROs) and 14 of the world's top 20 pharmaceutical companies have adopted Medable's technology.

2. **Global Reach**: Medable's technology has been deployed in 300 clinical trials across 60 countries and in over 100 local languages. This widespread usage has positively impacted the lives of more than one million patients and research participants worldwide.

3. **Decentralized and Hybrid ...
... Trials**: Medable's platform has enabled its customers to achieve impressive results in clinical trials, including a 200 percent faster enrollment rate and a 50 percent reduction in costs. This highlights the platform's effectiveness in streamlining clinical trial processes.

4. **Vision for Innovation**: The company is dedicated to ushering in a new era of drug development by accelerating the journey from scientific discovery to real-world impact. Their mission is to facilitate the development of new medicines through the integration of technology and science.

5. **Prix Galien Awards**: The Prix Galien Awards are organized by the Galien Foundation, a global institution that honors innovators in life sciences. This award recognizes the excellence of Medable's evidence generation platform as a significant contribution to digital health.

6. **Impact on Clinical Research**: Medable's software-as-a-service platform addresses the challenges of outdated processes in clinical research. It enhances the speed, data capture, and accessibility of clinical trials across various therapeutic areas, ultimately expediting the development of new medicines.

7. **Financial Benefits**: A financial modeling study conducted by the Tufts Center for the Study of Drug Development in 2022 shows that decentralized clinical trials (DCTs) utilizing Medable's platform can achieve substantial financial benefits, making them financially attractive for Phase II and Phase III trials.

Medable's innovative platform is transforming the landscape of clinical trials by improving efficiency, data collection, and accessibility. This recognition from the Prix Galien USA Forum underscores the company's commitment to advancing the field of healthcare through technology and innovation.

https://www.techdogs.com/tech-news/business-wire/medable-wins-2023-prix-galien-award-for-best-digital-health-solution